Involvement of Polymorphonuclear Neutrophils and Platelets in Severe Form of COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-04

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective is to quantify the population of reverse migrating neutrophils in patients with COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic

NCT06349707

Viral Pneumonia

COMPLETED

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

NCT04407689

COVID-19 Lymphocytopenia

TERMINATED PHASE2

Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)

NCT07076862

PASC Post Acute Sequelae of COVID-19

RECRUITING EARLY_PHASE1

Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19

NCT06142279

Certain Disorders Involving the Immune Mechanism

NOT_YET_RECRUITING NA

A Retrospective Study in Patients With Mild to Moderate COVID-19

NCT05374772

COVID-19

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-interventional transversal research whose main objective is to quantify the population of reverse migrating neutrophils in patients with COVID-19.

Design:

A multicentric (3 sites) clinical trial

Sample size :

200 patients

Population concerned:

Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.

Duration of participation (treatment + follow-up): until the patient is discharged from the ICU and within 2 months top.

No interim analysis is planned. Analysis will be performed at the end of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.

Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admitted to the intensive care units of Saint-Antoine, Tenon and Pitié-Salpêtrière hospitals (Paris, France)
* With moderate to severe respiratory distress syndrome and SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab
* informed and not opposed to participation in research
* included within 4 hours following the paatient's admission